By Colin Kellaher
Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer.
Bristol Myers on Friday said the approval covers the combination for the first-line treatment of adults with unresectable or advanced hepatocellular carcinoma.
Liver cancer is the third most frequent cause of cancer death worldwide, and hepatocellular carcinoma is the most common type of liver cancer, accounting for 90% of global cases, the Princeton, N.J., biopharmaceutical company said.
The Opdivo/Yervoy combination is already approved in several cancer indications worldwide. The U.S. Food and Drug Administration is reviewing the combination as a potential first-line treatment option for adults with unresectable hepatocellular carcinoma, with a target action date of April 21.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 07, 2025 07:12 ET (12:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。